Alzamend Neuro’s AL001 “Lithium in Brain” Study Kicks Off at MGH, Aiming to Redefine Alzheimer’s and Mood Disorder Treatments
With Topline Data by Year-End, AL001’s Head-to-Head Battle Against Lithium Carbonate Could Revolutionize the $15B Neuropsychiatric Market DENVER, Colo., May...